Click to EnlargeMarket Cap: $70M
Description from Yahoo! Finance
ImmunoCellular Therapeutics (NASDAQ:IMUC), a development stage company, focuses on developing and commercializing therapeutics to treat cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens; peptide based immunotherapies targeting cancer stem cells; and monoclonal antibodies to diagnose and treat various cancers.
Click to Enlarge Technical Analysis
The stock has been trading in a wide range since early 2010 and so far this year has made a big move to the upper end of this trading channel. Currently it is consolidating nicely, and as such, is working off its near-term overbought levels. Next big support is around the $1.50 level. On a break above the $1.90 level, the stock could accelerate and move toward $2.30 and eventually $2.60.